Related Party Transactions (Details)		1 Months Ended				12 Months Ended
	Apr. 26, 2016 $ / shares shares	Sep. 30, 2021 shares	Aug. 31, 2021 ft²	Feb. 28, 2021 USD ($) $ / shares shares	Mar. 31, 2018 USD ($) $ / shares shares	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Oct. 31, 2020
Public Offerings
Issuance of common stock | shares		1,457,947
Proceeds from sale of stock							$ 31,989,000
Owners of More Than 5% of Our Common Stock or Board of Directors
Area of property subleased | ft²			7,585
Sublease income - related party						$ 587,000	235,000
Angel Pharmaceuticals
Related Party Transactions
Clinical drug supplies						200,000
Owners of More Than 5% of Our Common Stock or Board of Directors
Internal personnel costs						100,000	200,000
Third-party costs						1,300,000	1,600,000
Third-party costs expensed in prior years						500,000	600,000
Third-party costs expensed in current years						800,000	1,000,000.0
Sublease income - related party						600,000	200,000
ICON plc
Owners of More Than 5% of Our Common Stock or Board of Directors
Clinical trial expense						$ 429,000	$ 246,000
Follow-on Public Offering
Public Offerings
Issuance of common stock | shares				9,783,660	8,117,647
Share offering price | $ / shares				$ 3.50	$ 8.50
Proceeds from sale of stock				$ 32,000,000.0	$ 64,900,000
Follow-on Public Offering | Orbimed Advisors LLC
Public Offerings
Issuance of common stock | shares				1,285,714
Owners of More Than 5% of Our Common Stock or Board of Directors
Aggregate Purchase Price				$ 4,499,999
Follow-on Public Offering | Richard A. Miller, M.D.
Public Offerings
Issuance of common stock | shares				100,000
Owners of More Than 5% of Our Common Stock or Board of Directors
Aggregate Purchase Price				$ 350,000
Over-Allotment Option
Public Offerings
Issuance of common stock | shares	502,618			1,212,231	1,058,823
Share offering price | $ / shares	$ 15.00
Angel Pharmaceuticals
Related Party Transactions
Ownership interest (as percent)						49.70%		53.20%